Latest Breaking News On - Biosimilar insulin glargine - Page 1 : comparemela.com

Share this article Share this article PITTSBURGH and BENGALURU, India, July 28, 2021 /PRNewswire/  Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug Administration (FDA) has approved Semglee ® (insulin glargine-yfgn) injection as the first interchangeable biosimilar product under the 351(k) regulatory pathway. Biocon Biologics Viatris CEO Michael Goettler commented: We are extremely proud to achieve the industry s first approval of an interchangeable biosimilar product in the U.S., which will help broaden access to this important diabetes medicine for patients, physicians, payers and providers. This is yet another important milestone for our company that not only continues to underscore the strength of our internal scientific capabilities, but also supports our belief in the promising future of our company as we continue to work to identify innovative ways to increase access to complex treatments f

United statesAndhra pradeshNew zealandKiran mazumdar shawRajiv malikArun chandavarkarBiocon biologicsViatris biocon biologicsEuropean free trade associationExchange commissionPfizer incEuropean unionViatris incViatris president rajiv malikExecutive chairpersonBiosimilar insulin glargine